Developments Opus Genetics doses first patient with gene therapy in LCAS Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer... September 7, 2023